Details of the Drug
General Information of Drug (ID: DMGE0CW)
Drug Name |
Glutethimide
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Alfimid; Doriden; Dorimide; Elrodorm; Gimid; Glimid; Glutathimid; Glutethimid; Glutethimidum; Glutetimid; Glutetimida; Glutetimide; Glutetimidu; Gluthetimide; Noxiron; Noxyron; Ondasil; Rigenox; Sarodormin; Glutetimide [DCIT]; Glutetimidu [Polish]; CC 11511; LT00114358; Doriden (TN); Doriden-sed; Glutethimide [INN:BAN]; Glutethimidum [INN-Latin]; Glutetimida [INN-Spanish]; Glutethimide (JAN/INN); Phenyl-aethyl-glutarsaeureimid; Phenyl-aethyl-glutarsaeureimid [German]; Alpha-Ethyl-alpha-phenylglutarimide; Alpha-Phenyl-alpha-ethylglutaric acid imide; Alpha-Phenyl-alpha-ethylglutarimide; 2-Ethyl-2-phenylglutarimide; 2-Phenyl-2-ethylglutaric acid imide; 3-Ethyl-3-phenyl-2,6-diketopiperidine; 3-Ethyl-3-phenyl-2,6-dioxopiperidine; 3-Ethyl-3-phenyl-2,6-piperidinedione; 3-Phenyl-3-ethyl-2,6-diketopiperidine; 3-Phenyl-3-ethyl-2,6-dioxopiperidine; 3-ethyl-3-phenylpiperidine-2,6-dione
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Hypnotics and Sedatives
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 217.26 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 1.9 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7192). | ||||
---|---|---|---|---|---|
2 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol. 2003 Aug;26(4):S9-16. | ||||
3 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
4 | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41. | ||||
5 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
6 | A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78. | ||||
7 | Neurosteroidogenesis in rat retinas. J Neurochem. 1994 Jul;63(1):86-96. | ||||
8 | Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38. | ||||
9 | Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. | ||||
10 | PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) | ||||
11 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. | ||||
12 | Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75. | ||||
13 | Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15. | ||||
14 | Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52. | ||||
15 | Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. | ||||
16 | Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702. | ||||
17 | Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. | ||||
18 | New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. | ||||
19 | Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. | ||||
20 | Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. | ||||